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ABSTRACT
Objective To compare cancer incidence in kidney
transplant recipients during periods of transplant
function (and immunosuppression) and after transplant
failure (when immunosuppression is ceased or reduced).
Design, setting,and participantsNationwide, population
based retrospective cohort study of 8173 Australian
kidney transplant recipients registered on the Australia
and New Zealand Dialysis and Transplant Registry who
first received a transplant during 1982-2003. Incident
cancers were ascertained using linkage with national
cancer registry records.
Main outcome measures Cancer-specific standardised
incidence ratios for periods of transplant function and for
dialysis after transplant failure. Incidence was compared
between periods using multivariate incidence rate ratios
adjusted for current age, sex, and duration of
transplantation.
Results All cases of Kaposi’s sarcoma occurred during
transplant function. Standardised incidence ratios were
significantly elevated during transplant function, but not
during dialysis after transplant failure, for non-Hodgkin’s
lymphoma, lip cancer, and melanoma. For each of these
cancers, incidence was significantly lower during dialysis
after transplant failure in multivariate analysis (incidence
rate ratios 0.20 (95% CI 0.06 to 0.65) for non-Hodgkin’s
lymphoma, 0.04 (0.01 to 0.31) for lip cancer, and 0.16
(0.04 to 0.64) for melanoma). In contrast, standardised
incidence ratios during dialysis after transplant failure
remained significantly elevated for leukaemia and lung
cancer, and cancers related to end stage kidney disease
(kidney, urinary tract, and thyroid cancers), with thyroid
cancer incidence significantly higher during dialysis after
transplant failure (incidence rate ratio 6.77 (2.64 to
17.39)). There was no significant difference in incidence
by transplant function for other cancers.
Conclusions The effect of immunosuppression on cancer
risk is rapidly reversible for some, but not all, cancer
types. Risk reversal was mainly observed for cancers with
a confirmed infectious cause. Risk of other cancers,
especially those related to end stage kidney disease,
remained significantly increased after reduction of
immunosuppression.
INTRODUCTION
A broad range of cancers, particularly those related to
infection, occur at excess rates after solid organ trans-
plantation—a situation similar to that seen in HIV
infection.
1 In HIV infection, the partial reversal of
immunodeficiency that is associated with anti-
retroviral therapy rapidly and substantially reduces
the risk of Kaposi’s sarcoma
2 and non-Hodgkin’s
lymphoma.
3 There are few data on whether the risk
of other cancers is also reduced.
4-6 In transplant recipi-
ents, clinical regression of cases of Kaposi’s sarcoma
78
and non-Hodgkin’s lymphoma
910has been described
after reduction of iatrogenic immunosuppression.
However, as in HIV infection, there are few data on
whether cancer risk is reduced when immunosuppres-
sion is ceased.
In kidney transplant recipients, transplant failure
generally leads to the reinstitution of dialysis and the
substantial reduction or complete withdrawal of
immunosuppression.
11 This offers a unique opportu-
nity to examine the cancer risk profile on reduction of
immunosuppression.
12 Recently, we showed that inci-
denceoflipcancer,
13non-Hodgkin’slymphoma,
14and
melanoma
15 decreased markedly after kidney trans-
plantfailureandreinstitutionofdialysis.Inthepresent
paper, we report on the site-specific pattern of cancer
occurrence during periods of transplant function and
during periods of dialysis after transplant failure in an
Australian cohort of kidney transplant recipients.
METHODS
Data sources
The Australia and New Zealand Dialysis and Trans-
plant (ANZDATA) Registry is a comprehensive,
population based registry of all patients commencing
maintenance dialysis or undergoing kidney
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16 Our
study cohort included all patients on the ANZDATA
Registry in Australia who first received a transplant
between 1 January 1982 and 30 September 2003
(n=8173). Incident cancers were ascertained through
probabilistic record linkage with the Australian
NationalCancerStatisticsClearingHouse,whichcon-
tains data on all diagnoses of incident invasive cancer
inAustraliasince1982,withtheexceptionofnon-mel-
anoma skin cancer.
17
For each matched record, we obtained the date of
cancer diagnosis and ICDO-3 and ICD-10 (inter-
national classifications of diseases) codes for topogra-
phy and morphology.
18 We also obtained the general
population’s cancer incidence rates by five year age
group, sex, calendar year, and state or territory, for
each year since 1982. Data were available to 2001,
2002, or 2003 depending on jurisdiction of cancer
registration.
Statistical analysis
Person years of follow-up were accumulated from the
date of first transplantation until the date of death, last
contact, the latest date for which cancer data were
available, or the first diagnosis of each type of cancer.
Cancer incidence was examined during periods of
transplant function and of dialysis after transplant fail-
ure. Person years and incident cancers during the first
threemonthsofeachperiodwereexcluded,ascancers
diagnosedwithinthistimewouldalmostcertainlyhave
developed in the preceding period.
For each period, we calculated cancer-specific stan-
dardised incidence ratios (with 95% confidence inter-
vals) by comparing the number of observed cases with
thatexpectedbasedontheapplicationoftheappropri-
ate populationcancerincidence rates.
19 Theexception
wasforKaposi’ssarcoma,inwhichweappliedpopula-
tion rates from 1982 because of the impact of AIDS
related Kaposi’s sarcoma in the years thereafter.
Comparison of period-specific standardised inci-
dence ratios may be confounded by differences in the
age and sex structure of the cohort over time. There-
fore, for each cancer, we used multivariate Poisson
regression to compute incidence rate ratios with 95%
confidence intervals comparingincidence during each
period, with adjustment for current age (time depen-
dent, single years), sex, and the cumulative duration
oftransplantfunction(timedependent,years).Forcan-
cers with zero cases during dialysis, we calculated a
median unbiased estimate of the incidence rate ratio
using exact Poisson regression adjusted for current
age (time dependent, <35, 35-50, ≥50 years), sex, and
durationoftransplantfunction(timedependent,<2,2-
4.99, 5-9.99, 10-14.99, ≥15 years).
20
A two sided P value of <0.05 was considered statis-
tically significant. All analyses were performed using
Stata version 10 (StataCorp, College Station, TX,
USA).
Grouping of cancers
Analyses were restricted to cancers or groups of can-
cers (anogenital, oral cavity, and oropharyngeal can-
cers) for which there were at least 10 cases in total.
For descriptive purposes, cancers were grouped
according to their association with infection, end
stage kidney disease, or immunodeficiency. Cancers
associated with infection were those for which there is
sufficient evidence of causality according to the Inter-
national Agency for Research on Cancer.
21 These
included Kaposi’s sarcoma (human herpesvirus type
8); immunosuppression related non-Hodgkin’s
lymphoma and Hodgkin’s lymphoma (Epstein-Barr
virus); anogenital, oropharyngeal, and oral cavity can-
cers (human papillomavirus); liver cancer (hepatitis B
virus and hepatitis C virus); and cancer of the stomach
(Helicobacter pylori).
Cancers associated with end stage kidney disease
(cancers of the kidney, urinary tract, and thyroid)
were those for which our group had previously
shown the relative risk to be at least doubled before
renal replacement therapy,
18 and for which there is
no, or a much smaller, excess risk in people infected
with HIV.
1 Remaining cancers were grouped accord-
ing to their association with immunodeficiency, based
on whether they occur at increased rates after both
solid organ transplantation and HIV infection accord-
ing to meta-data.
1
RESULTS
The study cohort comprised 7809 patients (4628
males, 3181 females), 364 patients having been cen-
sored because of exclusion of follow-up during the
first three months of each period. In total, 925 cancers
were identified; 33 (3.4%) of these were excluded
because they occurred in the first three months of the
transplant (n=11) or dialysis (n=22) period. This left
892 cancers identified over 59037 person years. The
median age of patients at first transplantation was
43 years. Failure of the first transplant necessitating
institution of dialysis occurred in 1820 (23%) patients,
and 668 (9%) underwent a second transplantation.
Three or more transplants were received by 66 (1%)
patients. In total, there were 51933 person years
(mean 6.9) during periods of transplantation and
7104 person years (mean 3.9) during dialysis after
transplant failure.
Incidence of cancer by transplant function
Thefigureshowsthe cancer-specific standardisedinci-
dence ratios for the periods of transplant function and
dialysis after transplant failure standardised by five
year age group, sex, state or territory, and calendar
year. It also shows the multivariate incidence rate
ratios comparing incidence during dialysis after trans-
plant failure with that during transplant function,
adjusted for current age, sex, and cumulative duration
of transplant function.
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ThestandardisedincidenceratioforKaposi’ssarcoma
(10 cases) was substantially elevated during transplant
function; multivariate analysis was not performed as
no cases occurred during dialysis after transplant fail-
ure.
The standardisedincidenceratio for non-Hodgkin’s
lymphomawassignificantlyelevatedduringtransplant
function,butnotduringdialysisaftertransplantfailure.
Inthemultivariateanalysiswithadjustmentforcurrent
year of age, sex, and the cumulative duration of trans-
plant function, cancer incidence was significantly
lower during dialysis after transplant failure than dur-
ing transplant function.
Standardised incidence ratios for cancers associated
with human papillomavirus infection (anogenital, oral
cavity, and oropharyngeal cancers) were significantly
elevatedduringtransplantfunction,butnotduringdia-
lysis after transplant failure. In multivariate analysis,
incidence was not significantly lower during dialysis
after transplant failure, including when all the cancer
sites associatedwithhumanpapillomaviruswere com-
bined (incidence rate ratio 0.24 (95% confidence inter-
val 0.03 to 1.74), P=0.157).
Standardised incidence ratios for stomach cancer
werenotsignificantlyelevated,andtherewasnodiffer-
encein incidencebetweenperiodsinmultivariateana-
lysis.
There were insufficient cases of other infection
related cancers, including Hodgkin’s lymphoma
(n=7) and liver cancer (n=4), for analysis.
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For cancers of the thyroid, kidney, and urinary tract,
standardised incidence ratios were significantly ele-
vated both during transplant function and dialysis
after transplant failure. In multivariate analysis, inci-
dence was significantly increased during dialysis after
transplant failure for thyroid cancer and was non-sig-
nificantlyincreasedforcancerofthekidney.Therewas
nodifferencein incidencebetweenperiodsforcancers
of the urinary tract.
Other cancers
Standardised incidence ratios were significantly ele-
vatedduringtransplantfunction,butnotduringsubse-
quent dialysis, for lip cancer and melanoma. For both
cancers, incidence was significantly lower during dia-
lysis after transplant failure in multivariate analysis.
Standardised incidence ratios for leukaemia and lung
cancer were significantly elevated during both trans-
plant function and dialysis after transplant failure,
and there was no difference in incidence between per-
iods in multivariate analysis. The standardised inci-
dence ratio for colon cancer was slightly elevated
during transplant function but not during dialysis
after transplant failure, and there was no difference in
incidence between periods in multivariate analysis.
Standardised incidence ratios were not elevated in
either period for cancers of the breast or prostate, and
there was no difference in incidence between periods
in multivariate analysis.
DISCUSSION
Among those cancers known to occur at increased
ratesinkidneytransplantrecipients,thepatternofinci-
denceduringdialysisaftertransplantfailurewashighly
variable. The incidence of Kaposi’s sarcoma and non-
Hodgkin’s lymphoma (the infection related cancers
most strongly related to immunosuppression in both
transplant recipients and people infected with HIV)
decreased markedly on reinstitution of dialysis. The
incidence of lip cancer and melanoma also declined
substantially. For each of these four cancer types, stan-
dardised incidence ratios were significantly elevated
during periods of transplant function, but not during
dialysis after transplant failure, suggesting that the
effect of immunosuppression on cancer risk was close
to completely reversible.
Standardised incidence ratios remained elevated
during dialysis after transplant failure for leukaemia
and lung cancer, and for cancers known to be related
toendstagekidneydisease(urinarytract,kidney,thyr-
oid).Infact, theincidenceofthyroidcancerwassignif-
icantly higher during dialysis after transplant failure
than during transplant function. There was no signifi-
cant variation in incidence for other cancers.
Strengths and limitations of the study
This study had several strengths, including the use of
national, population based registers of cancer and kid-
ney transplantation, the long period of follow-up, and,
unique to the ANZDATA Registry, the availability of
comprehensive data on consecutive periods of trans-
plantation and dialysis. The principal limitation was
limited statistical power with which to examine inci-
dence beyond the period of first transplantation for
the less common cancers. Nevertheless, this is the
first epidemiological study to examine site-specific
cancer incidence after transplant failure. Much larger
studieshavethepotentialtofurtherilluminatetherela-
tion between risk of specific cancer types and current
immune function.
Comparison with other studies
The reduction in incidence of Kaposi’s sarcoma and
non-Hodgkin’s lymphoma after transplant failure is
consistent with a role for current functional immunity
in the prevention of these cancers. Both Kaposi’s sar-
comaandnon-Hodgkin’slymphomaarecausallyasso-
ciated with infection by γ herpesviruses: Kaposi’s
sarcoma with human herpesvirus-8, and non-Hodg-
kin’slymphomawithEpstein-Barrvirusinalargepro-
portion of immunodeficient cases.
22 For both cancers,
reductioninimmunosuppressionallowsreconstitution
of control by herpesvirus-specific CD8 T cells.
2324
Consistent with the pattern seen in HIV infection,
23
our analyses suggest that restoration of immune func-
tion can prevent these cancers from occurring, even in
individuals with past intense immunodeficiency. A
similar pattern of rapid reduction in risk was not seen
forotherinfectionrelatedcancers,althoughrateswere
non-significantly lower during dialysis for cancers
related to human papillomavirus. Rates of human
papillomavirus related cancers decline little, if at all,
in the immune reconstitution associated with anti-
retroviral therapy in people infected with HIV.
4-6
Lip cancer and melanoma occur at increased rates
after solid organ transplantation and in HIV
infection.
1Thedeclineinriskoflipcanceronreinstitu-
tion of dialysis was of a similar magnitude to that seen
for Kaposi’s sarcoma and non-Hodgkin’s lymphoma.
The precise cause of increased risk of lip cancer in
transplant recipients remains unclear, although
human papillomavirus may play a role,
25 as may indi-
vidual immunosuppressive agents.
13 The marked
reduction in incidence of cutaneous melanoma
observedonreinstitutionofdialysisaccordswithasin-
gle previous case report of clinical and dermatoscopic
fadingofmelanocyticnaeviaftertransplantfailureand
removal of immunosuppression.
26 Melanoma has no
known infectious cause,but thereis reliable epidemio-
logical and biological evidence of a relation with
immune function.
15
Ratesofthyroidcancerareincreasedinpatientswith
end stage kidney disease, both before and during dia-
lysis, and after kidney transplantation,
18 and are not
increasedinHIVinfection.
1Inourcohort,riskofthyr-
oid cancer was six times higher during dialysis after
transplantfailure.Thehigherriskobservedduringdia-
lysis may reflect the metabolic consequences of
chronic renal failure, such as selenium deficiency,
27
which has been linked with thyroid cancer risk in one
nested case-control study.
28 Case reports of thyroid
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parathyroidism induced by hypocalcaemia have also
been described.
29
Rates of leukaemia, and cancers of the stomach,
lung, and colon are increased after kidney
transplantation
18 and, except for colon cancer, during
HIV infection.
1 Risk of these cancers was not asso-
ciated with currency of immunosuppression in this
study; this could suggest that they are not closely
related to current immune function or may simply
reflect a lack of statistical power. Rates of breast and
prostate cancer, which are not increased either after
solid organ transplantation or in HIV infection,
1 were
not increased at any stage and showed no particular
pattern with respect to currency of immunosuppres-
sion.
Conclusions and policy implications
The rapid reduction of risk on cessation of immuno-
suppression for certain viral and immunodeficiency
related cancers demonstrates that the effect of immu-
nosuppression is largely reversible for these cancers.
An opposite pattern of increased risk during dialysis
was observed for thyroid cancer, suggesting that a fac-
tor related to end stage kidney disease is important in
its pathogenesis. These findings may help inform the
managementofcancerriskaftersolidorgantransplan-
tation, as well as in HIV infection, where improve-
ments in immune function from new treatments are
changing the spectrum of cancer risk. They also offer
novel insight into the role of current functional immu-
nity in the prevention of cancer in the general popula-
tion.
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